C4 Imaging Receives $1.32m Phase II SBIR Grant

C4 Imaging LLC, a Houston-based developer of medical devices that enable clinicians to personalize patient treatment through image-guided procedures, received a $1.32m Phase II Small Business Innovation Research grant.

The National Cancer Institute of the National Institutes of Health provides the award.

The Phase II SBIR award will help fund the development of an enhanced multi-modality imaging marker based on C4 Imaging’s commercially available Sirius™ MRI Marker. The award will support a detailed development program; including product design, validation and manufacture, along with pre-clinical and clinical testing that will be performed in collaboration with the University of Texas MD Anderson Cancer Center.

This is the second NIH SBIR award for C4 Imaging, which has demonstrated a MRI Marker approach for radioactive seed localization that addresses the need to improve treatment assessment for men who undergo prostate brachytherapy.
Sirius™ is FDA approved for implantation in prostate cancer patients being treated with radioactive seeds (brachytherapy).

Led by Andrew Bright, President and CEO, C4 Imaging was awarded a US patent in September 2013, with additional patent protection for further applications awarded in September 2014.

FinSMEs

21/08/2015

Join the discussion